Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription 06.05.2019 2 Ann Oncol 1 BMC Cancer 1 Eur J Obstet Gynecol Reprod Biol 2 Gynecol Oncol 1 Nat Med

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
   Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
   Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
2. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
   ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
   Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

3. MATTE I, Garde-Granger P, Bessette P, Piche A, et al
   Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
   BMC Cancer. 2019;19:406.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

4. BOGANI G, Matteucci L, Tamberi S, Ditto A, et al
   RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
   Eur J Obstet Gynecol Reprod Biol. 2019;237:93-99.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

5. DANIELE G, Arenare L, Scambia G, Pisano C, et al
   Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
   Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
   PubMed     Text format     Abstract available
   
   
6. LEDERMANN JA
   Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
   Gynecol Oncol. 2019;153:213-214.
   PubMed     Text format    
   
   

   
   Nat Med

7. STOWER H
   Lymph removal not tied to positive outcomes.
   Nat Med. 2019;25:541.
   PubMed     Text format    
   
   

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: